11:40 AM EST - Theratechnologies Inc. : Announced that the abstract for the primary end-point results of the ibalizumab phase III study (TMB-301) has been selected for a late breaker oral presentation at the IDWeek Conference to be held in New Orleans, from October 26 to 30. Theratechnologies Inc.
shares T.TH are trading up $0.01 at $2.57.
